For investors looking for a systematic way to find high-growth market leaders, the CAN SLIM method, created by William O'Neil, stays a key strategy. It mixes strict fundamental study with important technical signs to find stocks with solid earnings momentum, support from large institutions, and leading traits, best bought during good market periods. This organized system tries to identify stocks early in major price increases.
A recent filter using main CAN SLIM rules has identified Medpace Holdings Inc (NASDAQ:MEDP) as a stock for more review. The Cincinnati-based firm offers full clinical development services to the biotechnology, pharmaceutical, and medical device fields, an area with steady need for external research.
Fundamental Health: The "C-A-N" Heart
The "C-A" in CAN SLIM stresses current and yearly earnings strength, places where Medpace shows notable health. The method looks for firms with rising quarterly profits and sales, along with a record of yearly growth.
- Current Quarterly Results (C): Medpace's latest quarter displays notable momentum, with earnings per share (EPS) rising 27.2% and revenue growing 32.0% against the same quarter last year. This passes the usual CAN SLIM limit of 20-25% growth, indicating solid current business performance.
- Yearly Earnings Gains (A): The company's growth is not only recent. Across the last three years, Medpace has recorded an EPS compound annual growth rate (CAGR) near 27.9%, clearly passing the system's search for gains of 25-50%. Also, its Return on Equity (ROE) of 98.3% is outstanding, showing very efficient use of investor money and matching the method's liking for profitable, well-run companies.
The "N" rule centers on new products, services, or market leadership. As a full-service clinical research organization (CRO), Medpace works in an active part of the healthcare system, helping the creation of new treatments. Its function is central to the "new" advances moving the biopharma field ahead.
Institutional and Market Picture: The "S-L-I" Elements
CAN SLIM states that the strongest fundamental stories are supported by market movement and institutional attention.
- Supply, Demand, and Financial Condition (S): Medpace has a very clean balance sheet with no debt, leading to a Debt/Equity ratio of 0.0. This sound financial state gives operational choice and reduces risk, a positive feature. While the system observes that smaller share float can be better, the main demand element is supported by strong quarterly sales and earnings growth.
- Market Leader or Follower (L): A main technical filter in CAN SLIM is relative strength, which judges a stock's price performance versus the wider market. Medpace now has a relative strength rating of 76.7, meaning it does better than over 76% of all stocks. This makes it a market leader, a vital label within the method, as leading stocks often keep leading.
- Institutional Support (I): The method prefers stocks with increasing institutional ownership but cautions against those where ownership is too high. Medpace's institutional ownership is 84.9%, which is under the 85% limit used in this filter. This implies there is still space for more institutional purchases, which can give continued demand.
Technical and Valuation Setting
A look at Medpace's technical analysis shows a varied image that needs thoughtful study within the CAN SLIM system. The stock's long-term and short-term trends are now negative, and it trades much below its 52-week high. This goes against the "M" (Market Direction) part of CAN SLIM, which suggests care when the overall market trend is not positive. Presently, both the long and short-term trends for the S&P 500 are negative, creating a clear obstacle.
However, the technical report states the stock is settling within a recent band and shows signals of institutional buying, which can sometimes come before a new rise. From a valuation view, the fundamental analysis report gives Medpace a firm score of 7 out of 10, noting its outstanding profitability and health grades, balanced by a neutral valuation score. Its P/E ratio matches the S&P 500 average but is somewhat less expensive than its industry group.
Summary
Medpace Holdings Inc shows a strong fundamental picture for CAN SLIM-focused investors, meeting several important points: high quarterly growth, excellent long-term yearly EPS gains, high profitability (ROE), no debt, firm relative strength, and suitable institutional ownership. The company's function as a service provider to new drug developers also fits the "New" products and services idea.
The major warning is in the technical and market view. The stock's negative trends and the wider market's softness directly oppose a central part of the CAN SLIM system, which stresses buying leaders only in established market rises. For a strict follower, this would probably put MEDP on a watchlist for possible later entry when the price movement and market setting get better, rather than suggesting a current buy.
This study came from a filter based on the CAN SLIM method. You can review the current filter and see other possible stocks by going to the O'Neill CANSLIM High Growth screen.
Disclaimer: This article is for information only and is not financial advice, a suggestion, or an offer to buy or sell any security. Investing has risk, including the possible loss of original funds. You should do your own study and talk with a qualified financial advisor before making any investment choices.